This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stewart A. Skinner, MB, BS; Angela G. Penney, BSc; Paul E. O'Brien, MD, FRACS

Arch Surg. 1991;126(9):1094-1096.

Abstract
• Sulindac (cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl) benzylidene] indene-3-acetic acid), an inhibitor of prostaglandin synthesis, has been reported to cause regression of colon polyps in patients with familial polyposis coli and Gardner's syndrome. We examined the effect of sulindac on the growth of primary colon carcinomas in rats. Colon tumors were induced in 18 rats by repeated subcutaneous administration of dimethylhydrazine. The site and diameter of each tumor were measured via laparotomy and colonoscopy. Rats were randomized to receive either sulindac (10 mg/kg) twice daily or vehicle (0.5% methylcellulose). After 4 weeks of treatment, the site and size of tumors in the colon were again recorded. In eight rats receiving sulindac, no new tumors were identified, while in 10 control rats, 13 additional tumors were found after treatment. There was a significantly greater increase in size of the tumors in the control group (56.4 mm for 26 tumors) compared with the rats receiving sulindac (9.3 mm for 14 tumors). We report that sulindac inhibits the rate of development and the rate of growth of colon tumors in the rat.

(Arch Surg. 1991;126:1094-1096)

Author Affiliations
From the Department of Surgery, Monash University, Alfred Hospital, Prahran, Victoria, Australia.

Footnotes
Accepted for publication January 12, 1991.

Reprint requests to the Department of Surgery, Monash Medical School, Alfred Hospital, Prahran, Victoria 3181, Australia (Dr O'Brien).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sulindac Sulfide Inhibits Epidermal Growth Factor-induced Phosphorylation of Extracellular-regulated Kinase 1/2 and Bad in Human Colon Cancer Cells
Rice et al.
Cancer Res. 2003;63:616-620.
ABSTRACT | FULL TEXT  

Epidemiology of colorectal cancer
Boyle and Leon
Br Med Bull 2002;64:1-25.
ABSTRACT | FULL TEXT  

Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues
Thun et al.
JNCI J Natl Cancer Inst 2002;94:252-266.
ABSTRACT | FULL TEXT  

Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation
Brown et al.
Gut 2001;48:660-666.
ABSTRACT | FULL TEXT  

Inhibition of Extracellular Signal-regulated Kinase 1/2 Phosphorylation and Induction of Apoptosis by Sulindac Metabolites
Rice et al.
Cancer Res. 2001;61:1541-1547.
ABSTRACT | FULL TEXT  

Effects of Piroxicam on Prostaglandin E2 Levels in Rectal Mucosa of Adenomatous Polyp Patients: A Randomized Phase IIb Trial
Calaluce et al.
Cancer Epidemiol. Biomarkers Prev. 2000;9:1287-1292.
ABSTRACT | FULL TEXT  

Inhibition of rat colon tumors by sulindac and sulindac sulfone is independent of K-ras (codon 12) mutation
de Jong et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2000;278:G266-G272.
ABSTRACT | FULL TEXT  

Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer
Peleg et al.
Arch Intern Med 1994;154:394-400.
ABSTRACT